New Recruiting Trial: Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia
WHY IT MATTERS
This Phase 2 trial is now actively recruiting newly diagnosed ALL patients without the Philadelphia chromosome, offering access to an investigational asparaginase formulation (JZP458) that may have improved tolerability compared to standard asparaginase.
Researchers are looking for patients with a type of blood cancer called acute lymphoblastic leukemia (ALL) to test a new treatment combination. The study will test whether adding a drug called JZP458 to standard chemotherapy works better than chemotherapy alone. This trial is just starting and will recruit patients beginning in April 2026.
NCT ID: NCT06738368 Title: Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia Status: RECRUITING Phase: PHASE2 Sponsor: University of Washington Start date: 2026-04-01 URL: https://clinicaltrials.gov/study/NCT06738368 Source: UniteRare clinical trials database
YOU CAN ACT ON THIS
If you or a family member has been newly diagnosed with Ph-negative ALL, contact the University of Washington or visit clinicaltrials.gov/study/NCT06738368 to learn about eligibility and enrollment locations.